Resiquimod, a topical drug for viral skin lesions and skin cancer.
about
Delivery of host cell-directed therapeutics for intracellular pathogen clearanceTickling the TLR7 to cure viral hepatitis.Trial Watch: Toll-like receptor agonists in oncological indications.Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγTrial Watch: Peptide-based anticancer vaccines.Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.Immunomodulator-based enhancement of anti smallpox immune responses.Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune PotentiatorsNew Treatment Options for Mycosis FungoidesCombinations of TLR ligands: a promising approach in cancer immunotherapy.Medical approaches to non-melanoma skin cancer.Toll-like receptors and skin cancer.Immunotherapeutic approaches for cancer therapy: An updated review.Biological Response Modifier in Cancer Immunotherapy.Toll-like receptors and cutaneous melanoma.Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo.[Stimulating Type I interferon response with small molecules: revival of an old idea].Structure Based Modeling of Small Molecules Binding to the TLR7 by Atomistic Level Simulations.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study.Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.
P2860
Q27006858-F661D725-9F6C-4FE1-A517-BE3EF6FE6FEFQ33690260-301ADC66-CB31-4912-B926-827D4081AE16Q33878578-B6ADCF9B-A771-4B2B-B4FF-1C44D96CFF75Q34438411-53B682F9-7DBD-4B33-9A71-95DE9FB1D4D7Q34483345-372562E8-DCAC-4ADE-99AE-3266C4296A06Q35218562-75A54B7E-3483-4729-A559-0BBBD940356BQ35391402-B046879D-70E2-40F8-B585-A459004CC2B0Q35826747-820686BE-66E7-41EE-80A7-AACD59B073A6Q36607086-0EBDABD2-2F45-4E0F-B504-1F7913D25C95Q37383587-4AF56778-4FD7-46DF-80E6-ECA59136C322Q38162923-8B1BC455-B3FA-43C4-80A2-74503EE1C7EFQ38205438-C8CF966C-5960-4ED6-BE31-E7AEAB2E1705Q38388102-BBFB8066-B164-4682-867C-97F7576150D6Q38848213-AC11E681-09DD-46DB-83DF-316E5D3EC9DBQ39023996-E67EB8AF-278F-4836-8066-CAC3CD27395AQ40867608-9B8E1062-7F58-43DD-9500-486169A0B774Q40932056-6A201B5D-D620-4C3A-B93B-2EED1FD853BFQ41719113-6B92E60F-F079-41AF-A94C-B257E8CF4F88Q49210038-CAF92A5B-0E94-454E-8878-CB367BBB0CF7Q49805153-4335C353-A172-4289-94CC-6AD3B8756759Q51736282-F113C758-37B1-418F-8DDC-2FDA8FB2DFFFQ53047113-F0B63EE8-EFB4-43B5-82B8-604822B6EA64
P2860
Resiquimod, a topical drug for viral skin lesions and skin cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Resiquimod, a topical drug for viral skin lesions and skin cancer.
@en
type
label
Resiquimod, a topical drug for viral skin lesions and skin cancer.
@en
prefLabel
Resiquimod, a topical drug for viral skin lesions and skin cancer.
@en
P2093
P2860
P1476
Resiquimod, a topical drug for viral skin lesions and skin cancer
@en
P2093
Christian Surber
Eggert Stockfleth
Thomas Meyer
P2860
P304
P356
10.1517/13543784.2013.749236
P407
P577
2012-12-04T00:00:00Z